Howdy partner: MD Anderson’s evolving industry collaboration strategy

The shifting balance between oncology candidates and patients available for trials, and the rise of complex modalities, is shaping the way MD Anderson builds partnerships and develops new assets.

University of Texas MD Anderson Cancer Center’s KRAS-focused collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX), announced Wednesday, exemplifies the longer commitments and “deeper level of integration” the institute is now prioritizing in its latest clinical trial alliances, said  Ferran Prat, who heads its Strategic Industry Ventures group...